Sundar Jagannath

Search results

• Data on Multiple Myeloma Described by Researchers at Mount Sinai Medical Center (Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/refractory Multiple Myeloma In ...)

  Sundar Jagannath & Deepu Madduri

  6/02/23

  1 item of Media coverage

  Press/Media

• Sundar Versus Goliath in the Fight Against Myeloma

  Sundar Jagannath

  9/01/23

  1 item of Media coverage

  Press/Media

• Recap: Experts at Mount Sinai Grapple With Best Practices in Multiple Myeloma

  Sundar Jagannath & Joshua Richter

  27/12/22

  1 item of Media coverage

  Press/Media

• New Findings from Icahn School of Medicine at Mount Sinai Describe Advances in Multiple Myeloma (Trial Designs and Endpoints for Immune Therapies In Multiple Myeloma)

  Erin Moshier, Joshua Richter, Guido Lancman, Samir Parekh, Sundar Jagannath, Ajai Chari & Hearn Cho

  8/12/22

  1 item of Media coverage

  Press/Media

• Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

  Sundar Jagannath

  21/11/22 → 22/11/22

  23 items of Media coverage

  Press/Media

• Caribou Biosciences Announces FDA Clearance Of IND Application For CB-011, An Allogeneic Anti-BCMA CAR-T Cell Therapy For The Treatment Of Relapsed Or Refractory Multiple Myeloma

  Sundar Jagannath

  21/11/22 → 22/11/22

  2 items of Media coverage

  Press/Media

• CaMMouflage Study to Evaluate Allogeneic Anti-BCMA CAR T Therapy in Multiple Myeloma

  Samir Parekh & Sundar Jagannath

  21/11/22

  1 item of Media coverage

  Press/Media

• Janssen Scientific Affairs LLC Researcher Updates Knowledge of Multiple Myeloma (Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma)

  Sundar Jagannath

  15/11/22

  1 item of Media coverage

  Press/Media

• More Novel Therapies Are on the Horizon in Multiple Myeloma

  Ajai Chari, Hearn Cho & Sundar Jagannath

  1/07/22

  1 item of Media coverage

  Press/Media

• Legend Biotech : to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Form 6-K

  Sundar Jagannath

  2/06/22

  1 item of Media coverage

  Press/Media

• Legend Biotech To Host Investors At The 2022 American Society Of Clinical Oncology (ASCO) Annual Meeting

  Sundar Jagannath

  31/05/22

  3 items of Media coverage

  Press/Media

• EMA Recommends Gene Therapy for Treatment of Multiple Myeloma

  Sundar Jagannath

  12/05/22

  1 item of Media coverage

  Press/Media

• Patients With Multiple Myeloma Incur High Healthcare Costs During Follow-up

  Sundar Jagannath

  25/04/22

  1 item of Media coverage

  Press/Media

• Second CAR T-Cell Therapy Approved for Multiple Myeloma

  Sundar Jagannath

  1/04/22

  1 item of Media coverage

  Press/Media

• FDA approves Janssen's Carvykti for multiple myeloma.(RX Retail Pharmacy: BRANDED DRUGS)

  Sundar Jagannath

  14/03/22

  1 item of Media coverage

  Press/Media

• FDA to Fast Track Review of Experimental Drug HPN217 to Treat Relapsed/Refractory Myeloma

  Sundar Jagannath

  11/03/22

  1 item of Media coverage

  Press/Media

• FDA’s Carvykti Approval Gives Patients Whose Myeloma Has ‘Failed Everything’ Another Chance to Attack the Disease

  Sundar Jagannath

  10/03/22

  1 item of Media coverage

  Press/Media

• FDA Approves Carvykti (ciltacabtagene autoleucel) BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Sundar Jagannath

  9/03/22

  1 item of Media coverage

  Press/Media

• United States : U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssens First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Sundar Jagannath

  7/03/22

  2 items of Media coverage

  Press/Media

• FDA Approval of Cilta-Cel Fast Tracks Multiple Myeloma Toward Curative Potential

  Sundar Jagannath

  7/03/22

  1 item of Media coverage

  Press/Media

• Multiple Myeloma Patients Get Second CAR T-Cell Therapy Amid Growing Demand

  Sundar Jagannath

  4/03/22

  1 item of Media coverage

  Press/Media

• Dr. Jagannath on the FDA Approval of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

  Sundar Jagannath

  3/03/22

  1 item of Media coverage

  Press/Media

• US FDA approves Janssen Pharma's Carvykti to treat relapsed or refractory multiple myeloma

  Sundar Jagannath

  2/03/22

  1 item of Media coverage

  Press/Media

• Carvykti Approved for Relapsed/Refractory Multiple Myeloma

  Sundar Jagannath

  2/03/22

  1 item of Media coverage

  Press/Media

• U.S FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Sundar Jagannath

  2/03/22

  1 item of Media coverage

  Press/Media